Microbiotix, Inc.-Product Pipeline Review-2015

Microbiotix, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07356CDB
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Microbiotix, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Microbiotix, Inc.-Product Pipeline Review-2015', provides an overview of the Microbiotix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Microbiotix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Microbiotix, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Microbiotix, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Microbiotix, Inc.'s pipeline products

Reasons To Buy

Evaluate Microbiotix, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Microbiotix, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Microbiotix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Microbiotix, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Microbiotix, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Microbiotix, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Microbiotix, Inc. Snapshot 6

Microbiotix, Inc. Overview 6

Key Information 6

Key Facts 6

Microbiotix, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Microbiotix, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Microbiotix, Inc.-Pipeline Products Glance 12

Microbiotix, Inc.-Clinical Stage Pipeline Products 12

Phase I Products/Combination Treatment Modalities 12

Microbiotix, Inc.-Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Microbiotix, Inc.-Drug Profiles 15

filociclovir 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

MBX-700 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

MBX-1162 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

MBX-500 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

MBX-701 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

MBX-900 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecules to Inhibit 30S RNA for Tuberculosis 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecules to Inhibit T3SS for Pseudomonas Aeruginosa Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

MBX-1090 Analogs 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MBX-2168 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

MBX-2319 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MBX-2329 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

MBX-2359 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

MBX-2402 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MBX-2546 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecule to Inhibit DNA Helicase for Infectious Diseases 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Small Molecules for Ebola Virus Infection 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules for Gram-Negative Bacterial Infections 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecules to Inhibit NPC1 for Filovirus Infections 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Inhibit bNOS for MRSA Infections 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit PSAC for Malaria 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Inhibit the Fatty Acid Synthesis for Pseudomonas Aeruginosa Infections 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Microbiotix, Inc.-Pipeline Analysis 42

Microbiotix, Inc.-Pipeline Products by Target 42

Microbiotix, Inc.-Pipeline Products by Route of Administration 43

Microbiotix, Inc.-Pipeline Products by Molecule Type 44

Microbiotix, Inc.-Pipeline Products by Mechanism of Action 45

Microbiotix, Inc.-Dormant Projects 46

Microbiotix, Inc.-Locations And Subsidiaries 47

Head Office 47

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

Microbiotix, Inc., Key Information 6

Microbiotix, Inc., Key Facts 6

Microbiotix, Inc.-Pipeline by Indication, 2015 8

Microbiotix, Inc.-Pipeline by Stage of Development, 2015 10

Microbiotix, Inc.-Monotherapy Products in Pipeline, 2015 11

Microbiotix, Inc.-Phase I, 2015 12

Microbiotix, Inc.-Preclinical, 2015 13

Microbiotix, Inc.-Discovery, 2015 14

Microbiotix, Inc.-Pipeline by Target, 2015 42

Microbiotix, Inc.-Pipeline by Route of Administration, 2015 43

Microbiotix, Inc.-Pipeline by Molecule Type, 2015 44

Microbiotix, Inc.-Pipeline Products by Mechanism of Action, 2015 45

Microbiotix, Inc.-Dormant Developmental Projects,2015 46

List of Figures

Microbiotix, Inc.-Pipeline by Top 10 Indication, 2015 8

Microbiotix, Inc.-Pipeline by Stage of Development, 2015 10

Microbiotix, Inc.-Monotherapy Products in Pipeline, 2015 11

Microbiotix, Inc.-Pipeline by Top 10 Target, 2015 42

Microbiotix, Inc.-Pipeline by Top 10 Route of Administration, 2015 43

Microbiotix, Inc.-Pipeline by Top 10 Molecule Type, 2015 44

Microbiotix, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of Microbiotix, Inc.; Microbiotix, Inc. - Key Therapeutics; Microbiotix, Inc. - Pipeline Overview and Promising Molecules; Microbiotix, Inc. - News; Microbiotix, Inc. - Latest Updates; Microbiotix, Inc. - Pipeline; Microbiotix, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 107820
Site License
USD 3000 INR 215640
Corporate User License
USD 4500 INR 323460



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com